Sutro Biopharma STRO EBIT
EBIT at other companies
Other financials
Where this comes from
Calculated from Sutro Biopharma’s reported figures.
Plus components not separately reported this period.
The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sutro Biopharma's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sutro Biopharma's EBIT?
- Sutro Biopharma (STRO) reported EBIT of -$29.66M in Q1 2026.
- How has Sutro Biopharma's EBIT changed year-over-year?
- Sutro Biopharma's EBIT increased by 56.7% year-over-year, from -$68.51M to -$29.66M.
- What is the long-term trend for Sutro Biopharma's EBIT?
- Over 3 years (2021 to 2025), Sutro Biopharma's EBIT has grown at a 17.1% compound annual growth rate (CAGR), from -$98.52M to -$158.37M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.